Registration now open for Advanced Therapies Europe 2025 – where innovation meets opportunity
Barcelona to host Europe’s exclusive leading cell and gene therapy conference, focused on curated connections, immersive content and meaningful outcomes.
London, UK, April 7, 2025 – Phacilitate is pleased to announce that registration is now open for Advanced Therapies Europe 2025, 2–4 September at the Hotel Arts, Ritz-Carlton, in Barcelona, one of Europe’s fastest-growing biotech hubs. This exclusive gathering brings together 500 pre-approved leaders from across the advanced therapies ecosystem for three days of high-impact content, curated networking and strategic deal-making.
Advanced Therapies Europe 2025 is not about scale – it’s about impact. With limited tickets available, a carefully selected speaker line-up and a venue designed to foster relaxed, real conversation, the event offers a unique setting to connect, collaborate and accelerate progress in advanced therapies.
With a focus on high-value, personalised connections and immersive content, Advanced Therapies Europe 2025 will deliver an unparalleled opportunity for biotech leaders, pharma, investors, regulators, academics and solution providers to collaborate, knowledge-share and broaden their network.
Registration is now live at https://advancedtherapieseurope.phacilitate.com, with Super Early Bird pricing available until 18 April. General Admission starts at £199, while Industry Admission – for vendors, manufacturers and solution providers – starts at £1,499. Places are limited to 500 to ensure a highly curated and impactful experience.
Over three thoughtfully curated days, attendees will engage with an agenda tailored to the most critical topics in cell and gene therapy. Key themes include investment and market trends, manufacturing and scale-up strategies, clinical development and commercialisation, emerging technologies and the evolving regulatory landscape across Europe and beyond. Delegates can expect deep-dive workshops, focused roundtables and highly interactive track sessions that encourage open discussion and practical knowledge sharing.
The first confirmed speakers for 2025 include leading voices from across the global advanced therapies landscape: Miguel Forte, Chief Executive Officer at Kiji Therapeutics; Thomas Carlsen, CEO, Novo Nordisk Cellerator; Ase Rosenqvist, Nordic Cell Therapy Business Unit, Johnson & Johnson; Eleuterio Lombardo, Director Cell Therapy Characterization, Takeda; Angela Vollstedt, Director Global R&D Cell & Gene Therapies Portfolio, Novartis. Each will bring unique perspectives to this year’s conversations—from cutting-edge platform innovation and commercial scale-up, to regulatory alignment and manufacturing leadership.
Returning for 2025 are two industry-leading summits—the Women in Advanced Therapies Congress and the Investment Summit—each providing dedicated spaces for mentorship, innovation and strategic alignment. Also reimagined for this year is the Innovation Exchange: spotlighting the most exciting breakthroughs from emerging biotech companies and offering a first look at the technologies shaping the future of advanced therapies, alongside curated networking with investors.
New for 2025: delegates can opt for an enhanced VIP experience—offering early access to the networking app, guaranteed entry to limited-capacity sessions, exclusive lounge access and a ticket to the welcome rooftop networking party at sunset. These added benefits ensure senior attendees maximise every moment.
Advanced Therapies Europe is designed to serve senior leaders across the advanced therapies ecosystem, including executives in biotech and pharma, scientific and clinical researchers, regulatory experts, manufacturing and operations professionals, investors, and commercial teams. Whether scaling therapies, navigating complex regulations, seeking strategic partnerships or exploring the next investment opportunity, every element of the agenda and networking experience is built to support the goals of industry leaders and drive progress.
“We’ve reimagined this year’s event to be more dynamic, interactive and connection-driven,” said Ingerid Sorgaard, Content Director at Phacilitate. “It’s not just about delivering content—it’s about facilitating the right conversations in the right settings. From curated roundtables and deep-dive workshops to rooftop networking and interactive discussion formats, every element is designed to spark meaningful connections, fresh insights and real collaboration.”
Speakers and sponsors will be announced in the coming weeks. For further information and to register, visit https://advancedtherapieseurope.phacilitate.com.
About Advanced Therapies Europe
Advanced Therapies Europe is where science meets strategy on the road to commercialisation. Designed to serve the unique needs of the European advanced therapies ecosystem, the event brings together biotech leaders, regulators, investors and solution providers to share knowledge, forge partnerships and accelerate the delivery of cutting-edge treatments to patients. From early research through to market access, Advanced Therapies Europe offers curated content, meaningful networking and the insights needed to drive progress across the continent and beyond.
To find out more, visit: www.phacilitate.com/advanced-therapies-europe
About Phacilitate
Phacilitate exists to help biotech progress on their commercialization journey, as well as to push the industry one step closer to delivering more life-changing treatments to patients. Phacilitate connects industry leaders through inspiring conferences, vibrant communities, and market intelligence. Phacilitate organizes conferences and networking events in both Europe and the US. These provide a venue for the advanced therapies sector seeking the commercialization of global therapies, and a global audience expanding further into the various markets worldwide.
Phacilitate also provides market insights and resources to the advanced therapies industry. These market insights have specific focuses on industry insights that range from trials, finance and investment, regulation, manufacturing, and specific therapeutic techniques.
Find out more, visit: www.phacilitate.com
